scholarly journals Prospective, randomized double blind comparative study of safety and efficacy of carvedilol versus atenolol in patients of mild to moderate hypertension

2017 ◽  
Vol 6 (7) ◽  
pp. 1678
Author(s):  
Swathi Ratnam R. ◽  
Usha Kiran P. ◽  
S. V. R. Rajasekhar ◽  
M. Prasad Naidu
Keyword(s):  
Blood Pressure ◽  
Moderate Hypertension ◽  
Treatment Phase ◽  
Study Groups ◽  
Response To Therapy ◽  
Double Blind ◽  
Once Daily ◽  
Significant Difference ◽  
The Mean ◽  
Atenolol Group

Background: Carvedilol is a new cardiovascular compound with the combined pharmacologic properties of nonselective ß-blockade and vasodilation. The Aim of the study was to compare the safety and antihypertensive efficacy of 25mg Carvedilol once daily with 50mg atenolol once daily in patients with mild to moderate essential hypertension.Methods: This was a single center study conducted in Rangaraya Medical College, Kakinada. 80 eligible patients with mild to moderate hypertension were randomized to receive 25mg Carvedilol once daily (40 patients) or 50mg atenolol (40 patients) in a double-blind 12-week treatment phase. At each visit 0, 4, 8 and 12 weeks of treatment, sitting Blood Pressure (BP) and heart rate were measured. The effect on BP reduction within the group is compared by paired “t”test and the effect on reduction of BP between two study groups compared by unpaired “t”test.Results: After 12 weeks of treatment, the mean reduction of SBP (Systolic Blood Pressure) with carvedilol is 22.33±8.31mmHg with no Significant difference (p >0.05) compared to atenolol group mean reduction in SBP of 21.37±10mm Hg. The mean reduction in DBP (Diastolic Blood Pressure) after completion of the study in carvedilol group is 6.75±4.82mm Hg with no Significant difference (p >0.05) compared to atenolol group mean reduction in DBP of 8.55±5.25mm Hg. No significant difference seen in the efficacy parameters of both the drugs. The incidence of adverse effects such as bradycardia, headache, nausea, vomiting, hypotension and rash is less with carvedilol.Conclusions: In patients with mild to moderate hypertension, there was no statistically significant difference between efficacy of carvedilol or atenolol with regard to the degree of reduction in BP or the percentage of patients achieving a response to therapy but carvedilol showed a better safety profile when compared to atenolol.

Experiences with Metoprolol Durules®, A Slow-Release Formulation in Hypertension

1980 ◽  
Vol 8 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Jaakko Tuomilehto ◽  
Aulikki Nissinen
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Final Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
The Mean

The antihypertensive effect and the tolerability of metoprolol Durules® have been studied in fifty-five patients with mild to moderate hypertension. The patients' diastolic blood pressure was ≥95 mm Hg in order to qualify for entry. Thirty-seven out of fifty-three patients completing the study (70%) were treated with metoprolol Durules® monotherapy throughout the study. The mean blood pressure was reduced from 153/101 to 138/92 mm Hg after metoprolol Durules® compared to placebo (p < 0.001). Twenty-seven patients received one Durules® daily and ten patients received two Durules® daily as the final dose. Of the sixteen patients not responding on metoprolol Durules®, six patients achieved satisfactory control, i.e. a diastolic blood pressure below 95 mm Hg, when given 200 mg metoprolol + 25 mg hydrochlorothiazide (HCT). The results indicate that most patients with, mild or moderate hypertension can be controlled with metoprolol Durules® monotherapy given once daily. The addition of HCT gives a significant benefit in moderate hypertension, where metoprolol monotherapy is not sufficient.

scholarly journals Hemodynamic response in laparoscopic cholecystectomy after magnesium sulphate versus clonidine administration

2018 ◽  
Vol 6 (10) ◽  
pp. 3239
Author(s):  
Vijaya P. Borkar Patil ◽  
Mayuri Ganeshrao Tambakhe ◽  
Sunil Shankarrao Lawhale ◽  
Jayshree J. Upadhye
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Magnesium Sulfate ◽  
Magnesium Sulphate ◽  
Hemodynamic Response ◽  
Double Blind Study ◽  
Double Blind ◽  
Vasopressin Release ◽  
Significant Difference ◽  
The Mean

Background: Magnesium and clonidine both inhibit catecholamine and vasopressin release. They also attenuate hemodynamic response to pneumoperitoneum.Methods: This randomized double-blind study was designed to assess which agent attenuates hemodynamic stress response to pneumoperitoneum better in 70 patients undergoing laparoscopic cholecystectomy.Results: After the administration of drug, heart rate in group M was mean 84.29 while in group C was mean 79.89. Thus, there was more fall in Heart rate in C group. After intubation, heart rate at 1min, 3 min, 5 min was 101.20, 96.69, 93.94 respectively in group M and in C group was 96.37, 85.83, 86.17 respectively with p values (0.12, 0.001, 0.008). After giving drug, there was fall in blood pressure in both groups but in C group, there was significant fall in systolic blood pressure. There was no significant difference in the mean diastolic BP in both the groups immediately at intubation (76.17±10.74 for group M and 78.86±10.48 for group C with p>0.05) as also at 3 min (63.29±8.76 for M group and 65.14±11.705 for clonidine with p>0.05) and 5 min (63.03±7.909 for magnesium sulphate and 67.69±13.588 for clonidine with p>0.05) following intubation. Thus, the rise in mean diastolic BP was statistically similar in both Group M and Group C. There was no significant difference in the mean for MAP in both the groups immediately at intubation (88.86±12.76 for magnesium sulphate and 91.74±11.59 for clonidine) as also at 3 min (73.17±10.019 for M and 75.80±12.849 for C group. But at 5 min (71.71±9.11 for magnesium sulphate and 77.66±13.715 for clonidine) following intubation with p<0.05 which is significant.Conclusions: Administration of magnesium sulfate or clonidine attenuates hemodynamic response to pneumoperitoneum. Although magnesium sulfate produces hemodynamic stability comparable to clonidine, clonidine blunts the hemodynamic response to pneumoperitoneum more effectively.

Synbiotic supplementation is not effective on breast milk selenium concentrations and growth of exclusively breast fed infants: a pilot study

2019 ◽  
Vol 89 (1-2) ◽  
pp. 73-79 ◽  
Author(s):  
Leila Nikniaz ◽  
Reza Mahavi ◽  
Alireza Ostadrahimi ◽  
Zeinab Nikniaz ◽  
Sharare Taghipour
Keyword(s):  
Pilot Study ◽  
Breast Milk ◽  
Graphite Furnace ◽  
Controlled Trial ◽  
Study Groups ◽  
Z Score ◽  
Double Blind ◽  
Significant Difference ◽  
The Mean ◽  
Synbiotic Supplementation

Abstract. In this randomized, double-blind, placebo-controlled trial, 57 lactating mothers were randomly allocated into two groups to receive a daily supplement of synbiotic (n = 30) which contained different probiotic strains (2.0 × 108 CFU) and fructooligosaccharide (394 mg) or a placebo (n = 27) for 30 days. Dietary intake was collected from lactating women by 24-hour recall method. Breast milk selenium contents were determined by atomic absorption spectrometry with graphite furnace. Weight for age Z-score (WAZ) and Height for age Z-score (HAZ) were evaluated for infants. Data analyses were assessed using nutritionist IV, Epi Info and SPSS software and presented as mean ± sd or SEM. The total mean breast milk selenium levels were 50.1 ± 16.1 mcg L−1. At the baseline, the mean breast milk selenium concentrations in the synbiotic and placebo groups were 51.7 ± 20.2 and 48.5 ± 12.1 mcg L−1. The mean breast milk selenium levels increased and decreased in the symbiotic and placebo groups respectively, which were not significant (p > 0.05). Also, comparison of the changes in breast milk selenium concentration showed no significant difference between the two study groups after the intervention. At the baseline, the mean WAZ and HAZ of infants whose mothers’ milk selenium was more than 60 mcg/l was significantly (P < 0.05) higher than for others. In this pilot study, no significant effect was observed by synbiotic supplementation, however, for concise conclusion, more human studies with higher doses of supplements and longer duration of supplementation are needed to determine the effects of synbiotic supplementation on breast milk selenium contents and infants’ growth.

scholarly journals The effect of Reiki on blood hypertension

2014 ◽  
Vol 27 (5) ◽  
pp. 479-484 ◽  
Author(s):  
Léia Fortes Salles ◽  
Luciana Vannucci ◽  
Amanda Salles ◽  
Maria Júlia Paes da Silva
Keyword(s):  
Blood Pressure ◽  
Repeated Measures ◽  
Study Groups ◽  
Control Group ◽  
Double Blind Study ◽  
Double Blind ◽  
Anova Model ◽  
Significant Difference ◽  
Before And After ◽  
Experimental Group

Objective Determining the immediate effect of Reiki on abnormal blood pressure. Methods An experimental, double-blind study, in which were included 66 hypertensive patients, randomized to the three following study groups: control, placebo and experimental. The intervention lasted 20 minutes, the control group remained at rest, the placebo group received an imitation of the studied technique (mock Reiki) and the experimental group received the Reiki technique. Blood pressure was measured before and after the intervention by the same person with the same instrument. Results There was a decrease in blood pressure in the three groups and the reduction was greater in the experimental group, followed by the placebo and the control group. The ANOVA model for repeated measures showed a statistically significant difference among the groups (p <0.0001). Conclusion Reiki had a positive effect on reducing abnormal blood pressure, suggesting to be a complementary technique for the control of hypertension.

scholarly journals Efficacy of Hawthorn fruit extract on blood pressure and quality of sleep in patients with hypertension along with sleep disorders: A randomized double-blind controlled trial

2021 ◽  
Vol 7 (4) ◽  
Keyword(s):  
Blood Pressure ◽  
Sleep Disorder ◽  
Controlled Trial ◽  
Intervention Group ◽  
Study Groups ◽  
Quality Of Sleep ◽  
Fruit Extract ◽  
Double Blind ◽  
Significant Difference

Objective: This study aimed to investigate the effect of Crataegus monogyna (C.monogyna) on controlling the blood pressure in patients with hypertension along with sleep disorder. Methods: This was a parallel double-blind, placebo-controlled trial study from May, 2018 to December, 2019. Total of 60 patients with hypertension and sleep disorder were randomly assigned to C.monogyna and placebo groups. The groups received C.monogyna and placebo capsules twice-daily for 8 weeks. The primary outcomes were the changes of systolic and diastolic blood pressure and Pittsburgh questionnaire’s scores from baseline measurements. The secondary outcomes were changes in serum biochemical markers from baseline. Results: Before treatment, there was no significant difference between study groups in terms of demographic data and outcomes (P>0.05) except body mass index (P=0.02). After treatments, the intervention group had a significant improvement in systolic and diastolic blood pressure compared to placebo ((118.14±6.76 vs 129.76±8.28, 95% CI: 7.54 – 15.69, P<0.001 and 77.14±5.32 vs 83.57±6.73, 95% CI: 3.17 – 9.68, P<0.001, respectively) analysis revealed no significant difference observed between study groups in terms of baseline characteristics and pre-and posttreatment laboratory tests. Also, none of the groups had superiority in terms of the Pittsburgh questionnaire’s scores (P=0.44); however, the intragroup analysis revealed significant improvements in the intervention group (P= 0.001). Conclusion: C.monogyna fruit extract as a supplementary medication has beneficial effects on controlling blood pressure and quality of sleep in patients with hypertension along with sleep disorders.

A Post-Marketing Acceptability Study in 11685 Patients of the Efficacy of Timolol/Bendrofluazide in the Management of Hypertension in General Practice

1987 ◽  
Vol 15 (2) ◽  
pp. 106-114 ◽  
Author(s):  
B. T. Marsh ◽  
M. J. Atkins ◽  
D. J. Talbot ◽  
I. T. Fairey
Keyword(s):  
Blood Pressure ◽  
General Practice ◽  
Adverse Event ◽  
Initial Dose ◽  
Moderate Hypertension ◽  
Once Daily ◽  
Continuous Therapy ◽  
Post Marketing ◽  
Blood Pressures ◽  
The Mean

A post-marketing acceptability study was performed in 11 685 patients to assess the efficacy and acceptability of 10 mg timolol/2.5 mg bendrofluazide in patients with mild to moderate hypertension in general practice. The initial dose was 1 tablet/day. This was adjusted at weekly intervals up to a maximum of 4 tablets/day or until blood pressures of ≤95 mmHg diastolic or, in patients of ≥60 years, ≤100 mmHg plus the patient's age (in years) systolic, were achieved. Stabilized patients were followed-up after 12, 24 and 48 weeks. Of the patients enrolled, 69% (8039) were successfully treated for at least 8 weeks, 26% (3033) were withdrawn and 5% (613) defaulted. One tablet/day was required by 61% of patients and 29% required 2 tablets/day to achieve stabilization. The mean reductions in systolic and diastolic blood pressures and pulse rate were 31 and 19 mmHg, and 11 beats/min, respectively. Over 60% of the patients enrolled were still taking timolol/bendrofluazide after 12 months' continuous therapy. The most frequently reported reason for withdrawal was an ‘adverse event’ which occurred in 15.4% (1805) of patients. Only 1.9% (217) failed to achieve target blood pressure on 4 tablets/day. This large study has shown timolol/bendrofluazide to be a highly effective and acceptable once daily therapy for mild to moderate hypertension in general practice.

Clinical Pharmacology of Quinapril in Healthy Volunteers and in Patients with Hypertension and Congestive Heart Failure

Angiology ◽  
1989 ◽  
Vol 40 (4_part_2) ◽  
pp. 360-369 ◽  
Author(s):  
Allen J. Sedman ◽  
Edward Posvar ◽  
Allen J. Sedman
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Congestive Heart Failure ◽  
Healthy Volunteers ◽  
Moderate Hypertension ◽  
Pressor Response ◽  
Blood Pressure Monitoring ◽  
Double Blind Study ◽  
Double Blind ◽  
Once Daily

Quinapril is converted to quina prilat, a long-acting angiotensin con verting enzyme (ACE) inhibitor, and is currently being studied for the treatment of hypertension and con gestive heart failure. In studies of healthy volunteers, single quinapril doses of 0.625 mg to 80 mg inhibited plasma ACE activity for up to forty- eight hours. Dose-related inhibition of angiotension I pressor response oc curred after administration of quina pril doses of 0.625 mg to 20 mg. In addition, plasma renin activity in creased and aldosterone and an giotensin II concentrations decreased following single or multiple doses of quinapril. Subsequently, dose-ranging stud ies were conducted in patients with mild to moderate hypertension and congestive heart failure. Pilot studies suggested that 5 mg of quinapril given once daily had minimal antihy pertensive effect. Therefore, a defini tive, multiple-dose, placebo-con trolled, double-blind study of 5, 10, and 20 mg once daily doses of quina pril was performed. Quinapril doses of 10 mg and 20 mg were statistically significantly superior to placebo (p < 0.05) in lowering sitting diastolic blood pressure (DBP), whereas 5 mg of quinapril had only marginal clini cal effectiveness. A twenty-four-hour blood pressure monitoring study in dicated that quinapril administered once or twice daily effectively low ered DBP in patients with mild to moderate hypertension. This study suggested, however, that some pa tients may not achieve sustained re ductions in DBP over the entire twenty-four-hour interval with quinapril administered once daily and may require twice daily therapy. In studies of patients with refractory congestive heart failure, acute favor able hemodynamic effects were dem onstrated after the administration of quinapril. Quinapril doses of 2.5 mg to 10 mg increased cardiac index by 30% and decreased peripheral vascu lar resistance and pulmonary capil lary wedge pressure by 20% to 30%.

scholarly journals The Effects of Intravenous Nitroglycerin Bolus Doses in Reducing Hemodynamic Responses to Laryngoscopy and Endotracheal Intubation

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Pouran Hajian ◽  
Shabnaz Sharifi ◽  
Mahshid Nikooseresht ◽  
Abbas Moradi
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Endotracheal Intubation ◽  
Arterial Blood Pressure ◽  
Study Groups ◽  
Intravenous Nitroglycerin ◽  
Hemodynamic Responses ◽  
Arterial Blood ◽  
Significant Difference ◽  
The Mean

Background. Hemodynamic responses to laryngoscopy and endotracheal intubation are transient in most patients. However, in some patients with a history of heart disease, systemic hypertension, or cerebrovascular disease, these may lead to dangerous complications. This study is aimed at determining the effectiveness of intravenous nitroglycerin bolus doses in reducing hemodynamic responses to laryngoscopy and endotracheal intubation. Material and Method. In this double-blind randomized controlled trial, 78 patients aged 18 to 65 years were randomly divided into three groups: 1 μg/kg dose of nitroglycerin (first group), 2 μg/kg dose of nitroglycerin (second group), and normal saline or placebo (third group). 26 samples were allocated for each group. Patients’ hemodynamic responses to laryngoscopy and endotracheal intubation were measured at different times. Data were analyzed using SPSS V 16. Results. Patients in the three study groups were similar in terms of age, sex, and weight. There was no significant difference between the mean saturation of peripheral oxygen (SPO2) and the mean heart rate between the three groups before endotracheal intubation and 1 to 10 minutes after intubation ( P > 0.05 ). The difference of mean arterial blood pressure between study groups was only significant in the first and fifth minutes after intubation. Mean systolic and diastolic blood pressure in the first, third, and fifth minutes after intubation was significantly lower in the intervention groups than the control group ( P < 0.05 ). However, no significant difference was observed between the intervention groups. The frequency of systolic blood pressure decrease was significantly different in the first and fifth minutes after intubation in the three study groups ( P < 0.05 ). Conclusion. Bolus doses of 1 and 2 μg/kg nitroglycerin in noncardiac elective surgery prevents the increase of mean systolic, diastolic, and arterial blood pressure but has no significant effect on heart rate after intubation.

A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension

1995 ◽  
Vol 9 (3) ◽  
pp. 401-406 ◽  
Author(s):  
Ming-Fong Chen ◽  
Chi-Yu Yang ◽  
Wen-Jone Chen ◽  
Chii-Ming Lee ◽  
Chau-Chung Wu ◽  
...  
Keyword(s):  
Controlled Release ◽  
Moderate Hypertension ◽  
Chinese Patients ◽  
Double Blind ◽  
Once Daily ◽  
Blind Comparison
Sign in / Sign up

Export Citation Format

Share Document